IMEXF (Imagin Medical) Current Deferred Taxes Liabilities: $0.00 Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Imagin Medical Current Deferred Taxes Liabilities?

Imagin Medical IMEXF -99.00% Current Deferred Taxes Liabilities is $0.00 Mil as of Jun. 2023.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Imagin Medical's current deferred tax liabilities for the quarter that ended in Jun. 2023 was $0.00 Mil.

Imagin Medical Current Deferred Taxes Liabilities Related Terms

Imagin Medical Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Imagin Medical's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagin Medical Current Deferred Taxes Liabilities Chart

Imagin Medical Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Imagin Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Imagin Medical (IMEXF) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Jun. 2023. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Imagin Medical and its competitors.
Is Imagin Medical's Current Deferred Taxes Liabilities too high?
Imagin Medical's current Current Deferred Taxes Liabilities is $0.00 Mil.
How does Imagin Medical's Current Deferred Taxes Liabilities compare to ABT and SYK?
Imagin Medical's Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Medical Devices & Instruments company?
A good Current Deferred Taxes Liabilities depends on the Medical Devices & Instruments industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Imagin Medical and its competitors. Imagin Medical's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagin Medical stock overvalued right now?
Imagin Medical (IMEXF) has a current Current Deferred Taxes Liabilities of $0.00 Mil. The current Current Deferred Taxes Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Imagin Medical (IMEXF), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagin Medical Business Description

Address 890 West Pender Street, Suite 600, Vancouver, BC, CAN, V6C 1J9
Imagin Medical Inc is a Urologic Oncology company developing technologies to visualize and treat urologic cancers, including bladder and prostate cancer, through minimally invasive surgery. The company's first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer, helping to improve the surgical management of this disease. Imagin's follow-on product, the enCAGE Coil is a device with 510(k) clearance for soft tissue ablation. Imagin intends to refine the disposable bipolar radio frequency-based probe for use in the treatment of prostate cancer and benign prostate hypoplasia (BPH) and submit appropriate FDA premarket applications for the new indications.